Retina

Advanced imaging and awareness of systemic risk factors are essential.

Highlights from the 2025 Heidelberg Engineering International SPECTRALIS Symposium—And Beyond

New financing will support the company's lead retinitis pigmentosa programme, among other projects

This phase 2b/3 trial follows new, positive 2-year data from the phase 2 ALTITUDE trial, in which sura-vec was well-tolerated in subjects with non-proliferative diabetic retinopathy

The agreement is for a planned clinical trial of AXPAXLI (also known as OTX-TKI) for the treatment of non-proliferative diabetic retinopathy (NPDR).

Sandoz will oversee commercialization of the product across the European Union (excluding Germany), Switzerland, Norway, Australia, Hong Kong, Vietnam, and Malaysia under the terms of the agreement.

Neurotech Pharmaceuticals announced the first commercial manufacturing, shipment, and surgical procedure of ENCELTO, the first and only FDA-approved treatment for adults with idiopathic Macular Telangiectasia Type 2.

Neurotech Pharmaceuticals performs the first ENCELTO procedure.

Sandoz will hold exclusive or semi-exclusive marketing rights in several European and Asian countries

AAVB-039 is the company’s gene therapy program for Stargardt disease secondary to biallelic mutation in ABCA4.

Ocular salvage and preservation of vision are essentially dependent on early diagnosis, and several studies have been conducted to identify the factors leading to delayed diagnosis at presentation.

An ophthalmologic examination revealed bilateral anterior uveitis, though the patient had no ocular complaints at presentation

João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases

In a press release, the National Institute for Health and Care Excellence announced the first-ever approval for a mitochondrial disease treatment.

Franklin shares how methotrexate significantly reduces reoperation rates in diabetic patients with retinal detachments, enhancing postoperative outcomes and vision.

In a press release, the National Institute for Health and Care Excellence announced the first-ever approval for a mitochondrial disease treatment

Survey reveals severe impact of Good Days underfunding on retina practices, with many patients experiencing vision loss due to delayed access to care.

GLP-1 therapies could impact long-term outcomes in diabetic retinopathy

An intravitreal implant shows promise in enhancing visual function and retinal structure in diabetic retinopathy patients, according to recent research.